Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variantsRonan P. Kelly, David S. Small, Sandra Close et al.|British Journal of Clinical Pharmacology|2011Cited by 50
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery diseaseThomas O. Bergmeijer, Paul A. Gurbel, Peter J Svensson et al.|Thrombosis and Haemostasis|2014Cited by 32
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery diseaseStefan James, David Erlinge, Suman Duvvuru et al.|Thrombosis and Haemostasis|2014Cited by 21
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathwaysDominick J Angiolillo, Oscar Ö. Braun, José Luis Ferreiro et al.|Thrombosis and Haemostasis|2013Cited by 18
AS-248: Prasugrel and Clopidogrel in Chinese CYP2C19 Allelic Variants following Maintenance DosesSandra C. Kirkwood, Ronan P. Kelly, Kathy McCorkle et al.|The American Journal of Cardiology|2009Cited by 2